{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:13:38Z","timestamp":1788401618246,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03650-z","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T09:25:37Z","timestamp":1780737937000},"page":"3994-4007","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Effectiveness of mRNA-1273 Versus Protein-Based NVX-CoV2705 Vaccination on COVID-19-Related Outcomes Among Insured Adults in the United States During 2024\u20132025: A Retrospective Matched Cohort Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Amanda","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Hensler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevena","family":"Vicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keya","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Patry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"3650_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jamainternmed.2025.7179","volume":"186","author":"EHA Koumans","year":"2026","unstructured":"Koumans EHA, Khan D, Trejo I, et al. Estimated burden of COVID-19 illnesses, medical visits, hospitalizations, and deaths in the US from October 2022 to September 2024. JAMA Intern Med. 2026;186:321\u201330.","journal-title":"JAMA Intern Med"},{"key":"3650_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.10650","volume":"6","author":"F Menegale","year":"2023","unstructured":"Menegale F, et al. Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis. JAMA Netw Open. 2023;6:e2310650.","journal-title":"JAMA Netw Open"},{"key":"3650_CR3","unstructured":"World Health Organization. Technical advisory group on COVID-19 vaccine composition. https:\/\/www.who.int\/groups\/technical-advisory-group-on-covid-19-vaccine-composition-(tag-co-vac). Accessed 27 Mar 2026."},{"key":"3650_CR4","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","volume":"184","author":"MS Gebre","year":"2021","unstructured":"Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell. 2021;184:1589\u2013603.","journal-title":"Cell"},{"key":"3650_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addr.2021.01.001","volume":"170","author":"J Pollet","year":"2021","unstructured":"Pollet J, Chen W-H, Strych U. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv Drug Deliv Rev. 2021;170:71\u201382.","journal-title":"Adv Drug Deliv Rev"},{"key":"3650_CR6","doi-asserted-by":"publisher","first-page":"938","DOI":"10.15585\/mmwr.mm7342a1","volume":"73","author":"KC Ma","year":"2024","unstructured":"Ma KC, et al. Genomic surveillance for SARS-CoV-2 variants: circulation of Omicron XBB and JN.1 lineages \u2014 United States, May\u00a02023\u2013September 2024. MMWR Morb Mortal Wkly Rep. 2024;73:938\u201345.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3650_CR7","unstructured":"U.S. Food and Drug Administration. Updated COVID-19 vaccines for use in the United States beginning in fall 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/updated-covid-19-vaccines-use-united-states-beginning-fall-2024. Accessed 1 Apr 2026."},{"key":"3650_CR8","unstructured":"U.S. Food and Drug Administration. NUVAXOVID (COVID-19 vaccine, adjuvanted) Package Insert and Patient Package Insert. (2025)."},{"key":"3650_CR9","unstructured":"U.S. Food and Drug Administration. SPIKEVAX (COVID-19 Vaccine, mRNA) Package Insert. (2025)."},{"key":"3650_CR10","unstructured":"U.S. Food and Drug Administration. FDA approves and authorizes updated mRNA COVID-19 vaccines to better protect against currently circulating variants. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently. Accessed 1 Feb 2026."},{"key":"3650_CR11","unstructured":"U.S. Food and Drug Administration. FDA authorizes updated Novavax COVID-19 vaccine to better protect against currently circulating variants. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-updated-novavax-covid-19-vaccine-better-protect-against-currently-circulating. Accessed 1 Feb 2026."},{"key":"3650_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf705","volume":"12","author":"AL Figueroa","year":"2025","unstructured":"Figueroa AL, et al. Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines against JN.1 subvariants in adult participants. Open Forum Infect Dis. 2025;12:ofaf705.","journal-title":"Open Forum Infect Dis"},{"key":"3650_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70120","volume":"19","author":"CL Delaunay","year":"2025","unstructured":"Delaunay CL, et al. COVID-19 vaccine effectiveness against medically attended symptomatic SARS-CoV-2 infection among target groups in Europe, October 2024\u2013January 2025, VEBIS primary care network. Influ Other Respir Viruses. 2025;19:e70120.","journal-title":"Influ Other Respir Viruses"},{"key":"3650_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.17402","volume":"8","author":"R Link-Gelles","year":"2025","unstructured":"Link-Gelles R, et al. Estimated 2023\u20132024 COVID-19 vaccine effectiveness in adults. JAMA Netw Open. 2025;8:e2517402.","journal-title":"JAMA Netw Open"},{"key":"3650_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11111711","volume":"11","author":"H Kopel","year":"2023","unstructured":"Kopel H, et al. Comparative effectiveness of bivalent (original\/Omicron BA.4\/BA.5) COVID-19 vaccines in adults. Vaccines. 2023;11:1711.","journal-title":"Vaccines"},{"key":"3650_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2115463","volume":"386","author":"BA Dickerman","year":"2021","unstructured":"Dickerman BA, et al. Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in U.S. veterans. N Engl J Med. 2021;386:105\u201315.","journal-title":"N Engl J Med"},{"key":"3650_CR17","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1007\/s12325-025-03117-7","volume":"42","author":"X Wang","year":"2025","unstructured":"Wang X, et al. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines among adults with underlying medical conditions: systematic literature review and pairwise meta-analysis using GRADE. Adv Ther. 2025;42:2040\u201377.","journal-title":"Adv Ther"},{"key":"3650_CR18","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s40121-024-00936-z","volume":"13","author":"S Kavikondala","year":"2024","unstructured":"Kavikondala S, et al. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines among older adults: systematic literature review and meta-analysis using the GRADE framework. Infect Dis Ther. 2024;13:779\u2013811.","journal-title":"Infect Dis Ther"},{"key":"3650_CR19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamainternmed.2022.2109","volume":"182","author":"BA Dickerman","year":"2022","unstructured":"Dickerman BA, et al. Comparative safety of BNT162b2 and mRNA-1273 vaccines in a nationwide cohort of US Veterans. JAMA Intern Med. 2022;182:739\u201346.","journal-title":"JAMA Intern Med"},{"key":"3650_CR20","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1016\/j.vaccine.2023.07.050","volume":"41","author":"B Liu","year":"2023","unstructured":"Liu B, et al. Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection. Vaccine. 2023;41:5587\u201391.","journal-title":"Vaccine"},{"key":"3650_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/2023.02.18.23286136","author":"SK Park","year":"2023","unstructured":"Park SK, et al. Comparative effectiveness of BNT162b2 and NVX-CoV2373 vaccines in Korean adults. medRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.02.18.23286136.","journal-title":"medRxiv"},{"key":"3650_CR22","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.vaccine.2024.02.021","volume":"42","author":"HK Kim","year":"2024","unstructured":"Kim HK, et al. Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean adults: a population-based observational study. Vaccine. 2024;42:1440\u20134.","journal-title":"Vaccine"},{"key":"3650_CR23","unstructured":"U.S. Centers for Disease Control and Prevention. People with certain medical conditions and COVID-19 risk factors. https:\/\/www.cdc.gov\/covid\/risk-factors\/index.html. Accessed 25 Mar 2026."},{"key":"3650_CR24","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1001\/jama.2020.20323","volume":"324","author":"SS Kadri","year":"2020","unstructured":"Kadri SS, et al. Uptake and accuracy of the diagnosis code for COVID-19 among US hospitalizations. JAMA. 2020;324:2553\u20134.","journal-title":"JAMA"},{"key":"3650_CR25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2147\/CLEP.S335621","volume":"13","author":"KE Lynch","year":"2021","unstructured":"Lynch KE, et al. Positive predictive value of COVID-19 ICD-10 diagnosis codes across calendar time and clinical setting. Clin Epidemiol. 2021;13:1011\u20138.","journal-title":"Clin Epidemiol"},{"key":"3650_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/14760584.2023.2290194","volume":"23","author":"C de Waure","year":"2024","unstructured":"de Waure C, G\u00e4rtner BC, Lopalco PL, Puig-Barbera J, Nguyen-Van-Tam JS. Real world evidence for public health decision-making on vaccination policies: perspectives from an expert roundtable. Expert Rev Vaccines. 2024;23:27\u201338.","journal-title":"Expert Rev Vaccines"},{"key":"3650_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.198069","volume":"10","author":"B Awakoaiye","year":"2025","unstructured":"Awakoaiye B, et al. Comparative analysis of adenovirus, mRNA, and protein vaccines reveals context-dependent immunogenicity and efficacy. JCI Insight. 2025;10:e198069.","journal-title":"JCI Insight"},{"key":"3650_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2022.105321","volume":"157","author":"F Hielscher","year":"2022","unstructured":"Hielscher F, et al. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens. J Clin Virol. 2022;157:105321.","journal-title":"J Clin Virol"},{"key":"3650_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106286","volume":"89","author":"C McLeod","year":"2024","unstructured":"McLeod C, et al. The platform trial in COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70\u00a0years old. J Infect. 2024;89:106286.","journal-title":"J Infect"},{"key":"3650_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2026.106727","volume":"92","author":"N Mazarakis","year":"2026","unstructured":"Mazarakis N, et al. Immunogenicity and efficacy over 12\u00a0months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: a randomised controlled trial in Australia. J Infect. 2026;92:106727.","journal-title":"J Infect"},{"key":"3650_CR31","doi-asserted-by":"publisher","DOI":"10.52225\/narra.v4i3.788","volume":"4","author":"Q Kamil","year":"2024","unstructured":"Kamil Q, et al. Comparative study of anti-SARS-CoV-2 receptor-binding domain total antibody titer before and after heterologous booster with mRNA-based COVID-19 vaccine. Narra J. 2024;4:e788.","journal-title":"Narra J"},{"key":"3650_CR32","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40121-026-01303-w","volume":"15","author":"P Kaplonek","year":"2026","unstructured":"Kaplonek P, et al. IgG4 neutralization and sustained total IgG Fc-effector functions following repeated SARS-CoV-2 vaccination with mRNA-1273. Infect Dis Ther. 2026;15:859\u201374.","journal-title":"Infect Dis Ther"},{"key":"3650_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106177","volume":"89","author":"FCM Kirsebom","year":"2024","unstructured":"Kirsebom FCM, Stowe J, Bernal JL, Allen A, Andrews N. Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study. J Infect. 2024;89:106177.","journal-title":"J Infect"},{"key":"3650_CR34","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1093\/cid\/ciae405","volume":"82","author":"KC Ma","year":"2024","unstructured":"Ma KC, et al. Effectiveness of updated 2023\u20132024 (monovalent XBB.1.5) COVID-19 vaccination against SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineage hospitalization and a comparison of clinical severity\u2014IVY Network, 26\u00a0hospitals, 18 October 2023\u20139 March 2024. Clin Infect Dis. 2024;82:e595\u2013603.","journal-title":"Clin Infect Dis"},{"key":"3650_CR35","unstructured":"U.S. Centers for Disease Control and Prevention. Supplementary Figure. SARS-CoV-2 variant proportion estimates for JN.1 lineages by month \u2014 National SARS-CoV-2 genomic surveillance, United States, June 8, 2024\u2013July 5, 2025. Morbid Mortal Week Rep (MMWR). 2026; 75"},{"key":"3650_CR36","doi-asserted-by":"publisher","first-page":"126961","DOI":"10.1016\/j.vaccine.2025.126961","volume":"54","author":"DW Lee","year":"2025","unstructured":"Lee DW, et al. mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice. Vaccine. 2025;54:126961.","journal-title":"Vaccine"},{"key":"3650_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01292-2","author":"N Vicic","year":"2026","unstructured":"Vicic N, et al. Evaluating the effectiveness of 2024\u20132025 seasonal mRNA-1273 vaccination against COVID-19-related hospitalizations and medically attended COVID-19 among adults aged \u2265 18\u00a0years in the United States: an observational matched cohort study. Infect Dis Ther. 2026. https:\/\/doi.org\/10.1007\/s40121-025-01292-2.","journal-title":"Infect Dis Ther"},{"key":"3650_CR38","doi-asserted-by":"publisher","first-page":"ofae695","DOI":"10.1093\/ofid\/ofae695","volume":"11","author":"H Kopel","year":"2024","unstructured":"Kopel H, et al. Effectiveness of the 2023\u20132024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States. Open Forum Infect Dis. 2024;11:ofae695.","journal-title":"Open Forum Infect Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03650-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03650-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03650-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:04:41Z","timestamp":1787385881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03650-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3650"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03650-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Amanda Wilson, Ekkehard Beck, Heather R. Hensler, Nevena Vicic, Keya Joshi, Emily Patry, Linwei Li, Jane Wang, and Chris Clarke are employees of Moderna, Inc. and may hold stock and\/or stock options in Moderna, Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a secondary analysis of de-identified data without access to personal identifying information and without direct enrollment of patients (e.g., in contrast to interventional studies or other primary data collection studies requiring patient participation). Thus, informed consent is not applicable. All patient-level and provider-level data within the database contain synthetic identifiers to protect the privacy of patients and data contributors. All study reports will contain aggregated data only that cannot be used to identify patients or physicians. Analysis data sets are Health Insurance Portability and Accountability Act (HIPAA) compliant. Per 45 CFR 46.104 d4, institutional review board (IRB) approval is not required for secondary research, which does not use any identifiable information and if the study team does not have the code key with which the information can be made identifiable. This study is therefore not considered human subjects research and exempt from requiring IRB oversight. For these reasons, we believe that this study qualifies for an exemption from IRB\/institutional ethics committee (IEC) review. Exemption determination and HIPAA full waiver of authorization will be sought, and the IRB\/IEC letter will be stored in the study file.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}